Podcasts about moffitt cancer center

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

June is recognized in the US as Caribbean-American Heritage Month. So what better time to say Sante! or Cheers! to recognize the important achievements of researchers working to support members of the Caribbean community. We speak with Dr. Dorothie Durosier Mertilus about how important it is it literally be able to speak someone's language; in her case French or Haitian Creole. We hear from from Dr. Clement Gwede, the scientist whose lab is out in the community. Coming at gaps in care from different angles means that patients can be supported in meaningful ways, to offer them the best outcomes. Learn more about our guests: Dr. Dorothie Durosier Mertilus, and Dr. Clement Gwede. Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Donna M. Fick, PhD, RN, GCNS-BC, FGSA, FAAN, a Professor and Director of the Center for Geriatric Nursing Excellence at the Penn State Ross and Carol Nese College of Nursing. Dr. Fick shares insights into her work on delirium research, validated screening tools like the UB-CAM, and the importance of interdisciplinary care in geriatrics. She also reflects on her recent presidency at the American Geriatrics Society, emphasizing advocacy, inclusivity, and the fight against ageism.Donna M. Fick, PhD, RN, GCNS-BC, FGSA, FAAN, is a Professor and the Director of the Center for Geriatric Nursing Excellence at the Penn State Ross and Carol Nese College of Nursing in University Park, Pennsylvania. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Welcome to today's episode where we explore the nuanced world of investigative interviewing in healthcare settings. My guest is Denise Bruscino, the Chief Diversion Officer at Moffitt Cancer Center in Florida. With a unique combination of nursing experience in inpatient settings and specialized training in behavioral analysis, Denise brings a rare perspective to healthcare investigations—hence her apt self-description as a "unicorn" in her field.In this enlightening conversation, Denise shares her expertise on developing effective interviewing techniques, training others in the art of investigation, and the delicate balance between clinical knowledge and interview skills. We discuss the importance of flexibility during interviews, preparation strategies for managers, and practical advice for organizations building their own interview programs.Whether you're in healthcare, compliance, human resources, or any field that requires skilled interviewing, Denise's insights offer valuable guidance for conducting meaningful and effective investigations.

My team at Moffitt Cancer Center helped save my life and I'm forever grateful for their brilliance, dedication, and friendship over the past 6+ years. This is a repost of the episode I did with them last year.  Being a guest on the PEP Talks podcast for providers and staff at Moffitt was an honor, a privilege, and a labor of love. Moffitt is an amazing place filled with amazing people dedicated to curing cancer.Side note: I know I've been off the radar for a couple of years -- life's been challenging and busy and full of good things. Meanwhile, in addition to my full-time job, I'm writing a book about dealing with cancer, developing public speaking opportunities, and working on arrangements for the apartment we just bought in Italy. It's been a lifelong dream and we're so excited! I'll do an episode about this in the not-to-distant-future, so you can come along for that process, as well. It's all part of the "etc." in "Life, Cancer, Etc."Keywords: Moffitt, H. Lee Moffitt Cancer Center, cancer diagnosis, sarcoma, cancerNote: I'm not a medical professional. Everyone in these podcasts is sharing their own experiences.You can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtcYou can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtc

Send us a textIn this episode of the 'Midlife with Courage' podcast, host Kim welcomes the magical Kimmie Sue Hall. They discuss Kimmie Sue's life in Orlando, Florida, her courageous journey helping a friend overcome alcoholism, her retirement from a 30-year career with Disney, and the personal trials faced when her son battled cancer. She also shares some glimpses into her role as the wife of a rockstar and how the unexpected end of REO Speedwagon changed how she saw her future playing out. The episode highlights themes of courage, family, and authenticity while sharing inspiring anecdotes about making dreams come true at Disney and providing support during challenging times. Kimmie Sue also shares plans for a meaningful upcoming concert and her son's involvement in cancer awareness and support. 00:00 Introduction to Midlife with Courage00:21 Meet Kimmie Sue Hall01:29 A Courageous Conversation04:46 Kimmie Sue's Magical Career at Disney12:49 Tommy's Battle with Cancer17:58 Facing the Unthinkable: A Mother's Strength18:44 Raising Awareness: Testicular Cancer19:38 Miracles and Mentorship20:18 Foundations and Family Support23:42 A New Chapter: College and Music26:02 A Farewell Concert for a Cause33:11 Final Thoughts and Messages"Courage is a very contagious thing." Dr. Philippe Spiess of Moffitt Cancer Center in Tampa Florida. If you would like to support the Moffitt Cancer Center through a donation, please go to this link: https://fundraise.moffitt.org/campaign/651751/donateSupport the showKim Benoy is a retired RN, Certified Aromatherapist, wife and mom who is passionate about inspiring and encouraging women over 40. She wants you to see your own beauty, value and worth through sharing stories of other women just like you.Would you like to get a "sneak" listen to each podcast? Subscribe to my website to get my weekly inspirational message and a link to that week's podcast a day ahead of everyone else! Just click the link below to get on the list! SUBSCRIBE WEBSITEFACEBOOK

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Rod Quilitz, infectious diseases pharmacotherapist at the Moffitt Cancer Center and Research Institute, presents his talk regarding the infectious diseases syndromes likely to be encountered when managing ID complications in an immunocompromised population. Dr. Quilitz begins by discussing risk factors for infection. He then goes on to discuss neutropenic fever management. The contrast between low grade and high grade neutropenia is also differentiated. Next, Dr. Quilitz discusses strategies for prophylaxis of patients who have prolonged neutropenia, including the use of gram positive antimicrobial agents and antifungals. Other subjects covered include the spectrum of CART toxicities, immune reconstitution, prophylaxis for Pneumocystis, CMV disease/prophylaxis, and other viral infections in the immunocompromised population.

Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer. --- TIMESTAMPS 00:00 - Introduction 05:40 - Patient Selection Criteria 09:49 - Workflow 19:17 - Procedure Timing and Coordination 29:39 - Challenges and Considerations in Drug Dosing 32:39 - Optimizing Treatment Cycles and Patient Response 37:56 - Managing Post-Treatment and Adverse Effects 43:43 - Future Research and Gaps in Current Interventions 50:45 - Exploring New Applications for PHP Therapy 55:02 - Conclusion --- RESOURCES Hepzato: https://hepzatokit.com/ FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study: https://pubmed.ncbi.nlm.nih.gov/38704501/ FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A): https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510 Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial: https://pubmed.ncbi.nlm.nih.gov/36624292/ Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/ Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/ Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/ Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases: https://pubmed.ncbi.nlm.nih.gov/38587534/

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Michelle Talley, PhD, CRNP, ACNP‐BC, FAANP, FAAN, FNAP, an Associate Professor and Associate Dean for Clinical and Global Partnerships at the University of Alabama at Birmingham School of Nursing. She also serves as the Director of the PATH Clinic.Dr. Michelle Talley, PhD, CRNP, ACNP‐BC, FAANP, FAAN, FNAP, is an Associate Professor and Associate Dean for Clinical and Global Partnerships at the University of Alabama at Birmingham School of Nursing. She also serves as the Director of the PATH Clinic.Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Send us a text In this episode of Causes or Cures, Dr. Eeks chats with Dr. Timothy Yeatman about  the connection between diet, inflammation, and colon cancer. He'll explain why cancer can be thought of as a "poorly healing chronic wound" and describe his recent study highlighting how chronic inflammation, fueled by dietary choices, plays a key part in the progression of colorectal cancer. We'll explore the alarming rise of colon cancer in adults under 50 and any common patterns he's observed in this population. Dr. Yeatman will shed light on the immune tumor microenvironment, how it influences colon cancer, and its potential role in future treatments. Plus, we'll discuss natural approaches to prevention and treatment, including key lifestyle interventions, such as achieving the right balance of omega-3s and omega-6s.  Dr. Yeatman is the Associate Center Director for Translational Research and Innovation at Tampa General Hospital Cancer Institute and a Professor of Surgery at the University of South Florida. With a career spanning leadership roles at Intermountain Healthcare, the Huntsman Cancer Institute, and Moffitt Cancer Center, he has spearheaded groundbreaking research in colorectal cancer, genomics, and biomarker development. He founded the Guardian Research Network, led a $100M Moffitt-Merck collaboration, and co-founded M2Gen, a biotech company. His work has been funded by the National Cancer Institute since 1993, and he continues to advance cancer research and clinical innovation. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here.Support the show

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Amber Orman, MD, DipABLM is a double board-certified radiation oncologist and lifestyle medicine specialist focusing on breast cancer treatment and prevention, providing holistic care that encompasses mind and body. She joined AdventHealth from Moffitt Cancer Center and the University of South Florida Morsani School of Medicine in Tampa, where she served as staff and medical faculty, respectively. She is the first ever Chief Wellness Office (CWO) of AdventHealth Medical Group, working to improve the well-being of her colleagues. She is also the co-founder of the HEAL (Healthy Eating and Active Lifestyle) program at AdventHealth in Orlando, Florida. HEAL is an 8-week lifestyle medicine program designed to educate and inspire cancer patients to make positive changes to decrease cancer recurrence and improve overall healthspan. She collaborates with the American College of Lifestyle Medicine as a member of the Health Systems Council and was a past Chair of the Cancer Member Interest Group. She is the Medical Director of AdventHealth Lifestyle Ventures as well as an Assistant Professor at the University of Central Florida College of Medicine. Her research interests include integrative therapies and their applications to cancer prevention, treatment and survivorship, with a strong emphasis on nutrition.

February 11, 2025: Erica Williams, RTO of Texas for Ascension, sits down with Beth Lindsay Wood, CIO and CTO at Moffitt Cancer Center, to explore the pivotal moments that have shaped her journey in healthcare technology. From leading digital transformation efforts like CancerX and AI-driven clinical outcomes to navigating a career pivot between provider and consulting roles, Beth shares hard-won lessons on leadership, adaptability, and resilience. What does it take to recognize when a career change is necessary, and how do setbacks become stepping stones to greater success? Join this deep dive into the realities of leadership, career progression, and the essential skills needed to drive meaningful change in healthcare.Key Points:04:46 Career Setbacks and Pivoting11:45 Developing Leadership Traits16:06 Hiring and Team Building22:44 Keys to SuccessSubscribe: This Week HealthTwitter: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Research is so critical to the field of surgery worldwide. But how does the world of academic surgery compare in the UK? Join BTK fellow Jon Williams and ASGBI partner Jared Wohlgemut  for another installment of our BTK/ASGBI collaborative series where we take a deep dive investigating the many facets of surgical research–everything from getting started, funding, collaboration, mentorship, and sage advice from two incredibly successful academic surgeons. Professor Susan Moug represents the UK while Dr. Lesly Dossett represents the US in this excellent episode for any trainee or surgeon who is academically-inclined. After listening, you get to decide–who does it better?? UK or US? Professor Moug is an Honorary Professor at the University of Glasgow, Scotland. She is a Consultant Colorectal and Robotic surgeon at Golden Jubilee National University Hospital in Clydebank, and at the Royal Alexandra Hospital in Paisley, Scotland. She is also the Director of Research for the Association of Surgeons of Great Britain and Ireland since 2021, and the Surgical Specialty Lead for Colorectal Research at the Royal College of Surgeons of England. She has been awarded a Senior Fellowship from the Chief Scientist Office of the Scottish Government, and was the chief investigator for the Emergency Laparotomy in Frailty multicentre study, and the No-Laps follow-on study. Essentially, she is one of the leading researchers in emergency surgery in the UK, having been awarded over 1 million in grant funding for this under-researched and underfunded area. Dr. Dossett is an associate professor and surgical oncologist at the University of Michigan. After completing her undergraduate degree at Western Kentucky University, She completed both medical school and her general surgery residency at Vanderbilt University in Nashville, TN, during which she obtained an Agency for Healthcare Research and Quality training grant as well as a Masters in Public Health during research time. Following residency, she served as an active duty staff surgeon in the US Navy for several years before pursuing surgical oncology fellowship training at Moffitt Cancer Center. In 2016 she came on to University of Michigan as faculty and has since held numerous academic leadership roles both institutionally and nationally, including vice chair for faculty development, chief of the division of surgical oncology, and president of the Surgical Outcomes Club. Dr. Dossett has an impressive portfolio of research work focusing on implementation and de-implementation of comprehensive cancer care, which is funded through multiple NIH grants.  If you enjoyed this episode, stay tuned for more upcoming BTK/ASGBI collaborative content. If you have any questions or comments, please feel free to reach out to us at hello@behindtheknife.org.  ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing

In this piece, recorded at Anesthesiology 2024 in Philadelphia, TopMedTalk explores the evolving landscape of patient safety and quality standards in anesthesia. What have been the significant shifts in patient safety culture? What is the importance of a proactive approach to risk management in anesthesia? We mention this excellent article: https://www.apsf.org/article/why-should-i-obtain-the-certified-professional-in-patient-safety-cpps-credential/ Desiree Chappell, Mike Grocott and Monty Mythen speak with their guest, Jonathan Cohen, anesthesiologist, Vice Chair of Quality & Safety in the Department of Anesthesiology at Moffitt Cancer Center in Tampa, Florida, Associate Professor at the University of South Florida, Clinical Assistant Professor in the Department of Medical Education at University of Illinois Chicago, Faculty for the Institute of Healthcare Improvement's (IHI) Certified Professional in Patient Safety Course.

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.

Join us for an enlightening discussion with Marc Perkins-Carrillo, Chief Nursing Informatics Officer at Moffitt Cancer Center, as he shares his background and recent successful projects. Marc delves into his priorities for the next 12 months and anticipates changes in his role and teams, providing valuable insights into nursing informatics in oncology care.

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHMF24).

Send us a textRED Episode 300 SHOW NOTESSHOUT OUTSIf you want a shoutout on the show for you or someone you love, email us at info@runeatdrink.net or call us at 941-677-2733 and leave a message.Thank you to EVERYONE in the Runcation Nation.  We could not have made it to 300 episodes without your support, encouragement, and listening to us banter on and on for the last 300+ shows.  Thank you.  It means so much that we can't even put it into words.Thanks to all our patrons and everyone in the Runcation Nation for your support and encouragement.  Because of you, we have kept the show going over the last two years, so thank you!  Don't forget that you can bid on items in the online auction we are running to support Moffitt Cancer Center.  Thank you to Dean Gerber, Associate Producer of our show, and Josh Ozbirn, Executive Producer of the podcast, too!  Support the Moffitt Cancer Center!In this episode, we talk with Bill Manley, Sales and Marketing Director for Foothills Brewing, and Nikki Popovich, Marketing Director for 311 Endurance Events.  They were so generous with their time that they donated an entry to an event made for Runcationers like us… the CraftHalf!Find Mike and great beer from Foothills here:https://www.foothillsbrewing.com/Find Nikki and other awesome events here:junction311.com/Bid on items in our Facebook Album https://www.facebook.com/media/set/?set=a.1134574812001753&type=3 Please donate to our Fundraiser for Moffitt Cancer Center https://runsignup.com/2024runcationnationThanks to everyone who donated items including:ekhartyoga.com junction311.com/jeffgalloway.com medalchasersvrc.com 1905familyofrestaurants.com fitzness.com coastaldayzbrewery.com runeatdrink.net purecreativeapparel.com  Support the showTHAT'S A WRAP! Thank you for listening! Because of your support, we are in our eighth year of the podcast! Don't forget to follow us and tell us where to find you next on our website, Facebook, Instagram, and Twitter. Also, check out our store on the website and get some swag, thanks to Pure Creative Apparel. Thanks to www.PodcastMusic.com for providing the music for this episode, too!

In this episode, Veena Lingam, Associate Chief Medical Information Officer at Moffitt Cancer Center, discusses her transition into the role and the organization's strong focus on investing in both informatics solutions and personnel. She shares her excitement about developing a clinical informatics fellowship program and the challenges of building a talent pipeline for this critical, yet often overlooked, healthcare role.

Scientists are using the power of mathematics to take action against cancer. These unique analytical methods have contributed to an exciting new approach to cancer investigation and treatment. Joining us on this episode is Dr. Alexander (Sandy) Anderson, Ph.D. Dr. Anderson is the Chair of Integrated Mathematical Oncology at Moffitt Cancer Center. Dr. Anderson researches the mathematical modeling of cancer in order to develop eco-evolutionary therapies that can control cancer – rather than eradicate it.  Listen in to learn about: The “dialogue” between a growing tumor and its changing environment. How scientists are using mathematics to understand complex biological phenomena. What it takes to construct mathematical models that translate to cancer treatment strategies. Is mathematical modeling the future of cancer research? Find out now from a professional at the forefront of this investigative approach. To find out more about Dr. Anderson and his work, visit www.mathematical-oncology.org and www.moffitt.org. Upgrade Your Wallet Game with Ekster!  Get the sleek, smart wallet you deserve—and save while you're at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5  Smarter, slimmer, better. Don't miss out! Episode also available on Apple Podcast: http://apple.co/30PvU9C

In this episode, Veena Lingam, Associate Chief Medical Information Officer at Moffitt Cancer Center, discusses her transition into the role and the organization's strong focus on investing in both informatics solutions and personnel. She shares her excitement about developing a clinical informatics fellowship program and the challenges of building a talent pipeline for this critical, yet often overlooked, healthcare role.

Celeste Bello, MD, Moffitt Cancer Center, Tampa, FL Recorded on November 21, 2024 Celeste Bello, MD Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Join us as we dive into bispecific antibodies with Dr. Celeste Bello from Moffitt Cancer Center, exploring their mechanisms of action, current indications in lymphoma, and strategies for patient selection and administration. Dr. Bello also discusses side effects, management strategies, and emerging trends in bispecific therapies. Tune in today to learn more!

Why does it matter if someone identifies as LGBTQ+ or is recognized as a sexual gender minority? What do these terms even mean, and why are they relevant to cancer care? Dr. Matthew Schabath talks about this and more as he describes his work as an epidemiologist, initiatives using AI in diagnosis, and a researcher studying health disparities in the LGBTQ+ community. Learn more about our guest Matt on his website: https://www.moffitt.org/research-science/researchers/matthew-schabath/ and a recent piece in the PARTNERS Magazine: https://www.moffitt.org/globalassets/pdfs/patient--family/advisory-program/partners-winter-2024.pdf Find out more about Moffitt's commitment to the LGBTQ+ community here: https://www.moffitt.org/about-moffitt/enterprise-equity/health-equity/commitment-to-the-lgbtq-community/ Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, Engagement, and Equity at Moffitt Cancer Center and Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc Email: coee-office@moffitt.org Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Aparna Gupta, DNP, FACHE, CPHQ, CRNP, the Vice President of Quality for the National Hospice and Palliative Care Organization, in Alexandria, Virginia.  Dr. Aparna Gupta, DNP, FACHE, CPHQ, CRNP, is the Vice President of Quality for the National Hospice and Palliative Care Organization, in Alexandria, Virginia.  Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Send us a textRED Episode 299 Run, Eat, and Drink for Moffitt Cancer Center at Miles for Moffitt SHOUT OUTSIf you want a shoutout on the show for you or someone you love, email us at info@runeatdrink.net or call us at 941-677-2733 and leave a message.Shout out to Janine, Big Ed, and Joe in New York, who gave us stellar recommendations for this episode.Thank you to everyone who donated items and bid on auction items to support The DONNA Foundation.  In this episode, we shout out the donations and winning bids!Thanks to all our patrons and everyone in the Runcation Nation for your support and encouragement.  Because of you, we have kept the show going over the last two years, so thank you!  Thank you to Dean Gerber, Associate Producer of our show, and Josh Ozbirn, Executive Producer of the podcast, too!  RUNMiles for Moffitt Benefitting Moffitt Cancer Centerhttps://runsignup.com/2024runcationnation  EATGarvies Point Restaurant and Brewery https://garviespointbreweryandrestaurant.com/lunch-menu/DRINKGarvies Point Restaurant and Brewery Flight of Brewshttps://garviespointbreweryandrestaurant.com/on-tap/  Support the showTHAT'S A WRAP! Thank you for listening! Because of your support, we are in our eighth year of the podcast! Don't forget to follow us and tell us where to find you next on our website, Facebook, Instagram, and Twitter. Also, check out our store on the website and get some swag, thanks to Pure Creative Apparel. Thanks to www.PodcastMusic.com for providing the music for this episode, too!

In this episode, breast radiologist, Dr. Robyn Roth, aka @theboobiedocs, talks with Dr. Dana Ataya, an associate professor of breast radiology at Moffitt Cancer Center. They discuss the crucial importance of yearly mammograms starting at age 40 for average-risk women and emphasize the rising incidence of breast cancer in younger women.The episode addresses the confusion surrounding screening guidelines, the significance of understanding personal breast cancer risk, particularly for Jewish and Black women, and the benefits of supplemental imaging like ultrasound and MRI for women with dense breast tissue.Additionally, common myths about mammography, such as the notion that they cause breast cancer, are debunked. The conversation highlights the importance of evidence-based screening methods and healthy lifestyle choices in cancer prevention. Dr. Dana shares her first song and music video, End the Confusion, to promote breast cancer screening awareness as well as her Moffitt Cancer Center band, The ReMissions band. Dr. Robyn also gives important breast cancer awareness updates.

In this powerful episode of Game Over: c*ncer, we delve into the transformative impact of collaborative research in pediatric oncology. Hosts Val Solomon, Director of Program Impact, and Dana Nichols, Executive Director of Cannonball Kids' cancer Foundation (CKc), are joined by special guest Dr. Jonathan Metts, a pediatric oncologist at Moffitt Cancer Center. Dr. Metts shares his inspiring journey from a kid motivated by his father's battle with cancer to a dedicated researcher at the forefront of developing safer, more effective treatments for children with solid tumors.Listen in as Dr. Metts discusses his innovative clinical trial focusing on tumor-infiltrating lymphocyte (TIL) therapy and the complex, multi-institutional collaborations that bring this groundbreaking research to life. Learn about the critical role of cellular therapies in advancing care for young cancer patients, and discover how organizations like CKc and others are uniting to fund, support, and drive vital research forward.Whether you're a supporter, family member, or advocate for change, this episode will inspire you to join the fight against pediatric cancer. Get ready to be part of Team CKc as we educate for change, provide tangible hope, and empower our community to make a difference.Support CKc's mission at cannonballkidscancer.org, and don't forget to like, subscribe, and share to educate for change.Connect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon-516b50b8/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/Learn more about the Cannonball Kids cancer Foundation: https://cannonballkidscancer.org/GameOverCancer. #PediatricCancer  #CannonballKidsCancer  #CancerResearch #ChildhoodCancerAwareness

The mission of Moffitt Cancer Center is to contribute to the prevention and cure of cancer. Their commitment goes beyond treatment—exploring every possible avenue to support their community. Sharing information is among the simplest tools and can in itself save lives. This episode addresses how podcasts can form one such tool to help improve health outcomes for the Black and African American community. Learn more about our guests: Dr. Steven Bradley: www.moffitt.org/providers/anthony-bradley/ His podcast: https://theblackdoctorspodcast.com/ Dr. Susan Vadaparampil: www.moffitt.org/research-science/researchers/susan-vadaparampil/ Follow Dr. Vadaparampil on LinkedIn. Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, Engagement, and Equity at Moffitt Cancer Center and Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc. Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Steven Posar, MD, the founder and CEO of GuideStar Eldercare in Crown Point, Indiana.Dr. Steven Posar, MD, is the founder and CEO of GuideStar Eldercare in Crown Point, Indiana.Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Congresswoman Jen Kiggans, AGNP, the U.S. Representative for Virginia's 2nd Congressional District, and a Geriatric Nurse Practitioner.Jen Kiggans, AGNP, is the U.S. Representative for Virginia's 2nd Congressional District, and a Geriatric Nurse Practitioner.  Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Karen Mack, DNP, MBA, APRN, the Executive Director at Nurses Improving Care for Healthsystem Elders at Rory Meyers College of Nursing at New York University in New York, New York.Karen Mack, DNP, MBA, APRN, is the Executive Director at Nurses Improving Care for Healthsystem Elders at Rory Meyers College of Nursing at New York University in New York, New York.  Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Health disparities in cancer care are driven by many different factors and many marginalized communities will be impacted in different ways. On the flip side, many socio-economic factors will mean that patients from diverse backgrounds will be impacted in similar ways. In this “Crossover” episode, Dr. Brandon Blue, host of Cancer in our Community, sits down with Dr. Sarimar Agosto Salgado, host of Cáncer en nuestra Comunidad. They discuss their experiences and the need to consider language, culture and representation while working to bring health equity to all their patients and their loved ones. Learn more about our hosts: Dr. Brandon Blue and Dr. Sarimar Agosto. This podcast is produced by: The Office of Community Outreach, Engagement, and Equity at Moffitt Cancer Center. Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading  

This episode is a recorded presentation delivered by Robert Gatenby, MD from the Moffitt Cancer Center during the opening plenary at the SNMMI 2024 Artificial Intelligence Summit, "AI In Action" held Feb 29 - March 1, 2024.  Dr. Gatenby has used evolutionary dynamics models to develop an adaptive therapy approach for the treatment of cancer which he describes during his talk.  Join this podcast and discover an innovative and effective approach to treating cancer – the use of evolutionary biology, mathematical oncology and radiopharmaceutical therapy.  

Anemia presents a significant challenge in the management of patients with low-risk myelodysplastic syndromes (MDS). Given the considerable potential for symptom burden associated with anemia in patients with MDS, health care professionals must prioritize enhancing quality of life when evaluating treatment options. In this episode, CANCER BUZZ speaks with David Sallman, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center, and Karley Trautman, DNP, ANP-BC, AGACNP-BC, senior instructor of Medical Oncology at Highlands Ranch Cancer Center, to discuss best practices in the management of anemia in low-risk MDS patients.  “The goal is still personalizing [treatment] for the patient. So say a patient feel[s] better when their hemoglobin is greater than 10 grams per deciliter, as an example. So you titrate or transition therapies until you achieve that…in order to make the patient's experience better.”—David Sallman, MD   “Two people that have the same hemoglobin level can have completely different symptoms. So it's really important that we don't just focus on the numbers, but we focus on how the patient is feeling and how they're functioning…so that if they're doing well, even at a lower number than something we might typically treat, we don't let that number drive how often we feel like they need to be seen, but we take it into account—[treating] the whole person.”—Karley Trautman, DNP, ANP-BC, AGACNP-BC   David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL   Karley Trautman, DNP, ANP-BC, AGACNP-BC Senior Instructor, Medical Oncology Highlands Ranch Cancer Center Denver, CO   This episode was developed in connection with the ACCC education initiative Anemia Mitigation & Optimal Care for MDS Patients and is supported by Bristol Myers Squibb.   Resources: ACCC Myelodysplastic Syndromes  ASH 2020 Treatment Algorithm Lower-Risk MDS 

On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.

Gabby Lehigh recently earned her PhD from the Department of Anthropology at the University of South Florida (USF). She holds a bachelor's degree from Indiana University of Pennsylvania and a master's degree in anthropology from USF. Her dissertation research focused on transformative psychedelic experiences at music events to understand how psychedelic use in everyday contexts creates meaningful and impactful experiences. She recently accepted a position as a research coordinator at Moffitt Cancer Center, developing novel interventions for smoking cessation among underserved populations. She is passionate about developing and supporting diverse clinical, spiritual, and recreational models of psychedelic (and other drug) use to expand accessibility for harm reduction and benefit enhancement. She believes everyone should have affordable and accessible access to these substances and treatments in the contexts they find most suitable for themselves. Gabby is also the co-founder and Managing Director of Psychedelic Grad, a web-based community for up-and-coming psychedelic professionals. In addition, she hosts the Psychedelic Grad podcast, Curious to Serious, where she interviews students and professionals in the psychedelic space on how they navigated the path from being curious about psychedelics to dedicating their careers to them.LinkedIn:www.linkedin.com/in/gabrielle-lehigh 671b2182PG:https://www.psychedelicgrad.comPodcast:https://open.spotify.com/show/1py4yZ8XY9pYkDoWQxed3B?si=b3cb4322b5a34f2a

Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostASCO2024/Skin).

Moffitt Cancer Center prioritizes a patient-centric approach to care. Jilian Manrique, MSN, RN, OCN, Director of Nursing- Infusion Services and MAC Blood Draw Services, at Moffitt Cancer Center, discusses how AI technology helped advance this mission and yield positive outcomes, like a 10% increase in volume without adding more chairs. Jilian also shares valuable insights on change management and best practices for implementing new technologies in infusion care.This episode is sponsored by LeanTaaS.

—- 

Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP, a Professor at the Northwestern University Feinberg School of Medicine; Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the University of Miami Sylvester Comprehensive Cancer Center; and Amer Zeidan, MBBS, MHS, an Associate Professor of Medicine at Yale University.

Anemia can negatively affect quality of life and treatment outcomes for patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina, and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.   “It really does take a village to manage the anemia of high-risk MDS…We as providers need to think through transfusion mitigation strategies but also keep our patients safe.” –Amy DeZern, MD, MHS   “Health disparities can play a really important role in affecting outcomes. And a lot of that is multifactorial—it may be due to patients without insurance having a higher tendency to delay seeking care due to the associated cost of seeking medical attention, and therefore they may present sicker.”—Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP “There's no question, especially as therapies are getting more complex, and the side effects as far as the severity of cytopenias are increasing, this collaboration between blood bank centers and community oncologists is going to be increasingly important.”—David Sallman, MD Amy DeZern, MD, MHS Director, Bone Marrow Failure and MDS Program Professor of Oncology and Medicine Johns Hopkins University School of Medicine Baltimore, MD   Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Charlotte, NC   David Sallman, MD Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida   This episode was developed in connection with an initiative of the ACCC education program Myelodyplastic Syndromes, Optimal Management of Anemia in Adults with High-Risk MDS, which is supported by Gilead.   Resources: Myelodysplastic Syndromes - ACCC Achieving & Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia Project - ACCC Disparities in Acute Myeloid Leukemia - ACCC  

"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP. This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at University of Miami Health. 

On this episode of FYI, Director of Next Generation Internet Research Frank Downing and Analyst Ali Urman interview Dr. Issam El Naqa, the founding chair of the Department of Machine Learning at the Moffitt Cancer Center. Dr. El Naqa shares his journey from electrical engineering to spearheading innovative uses of artificial intelligence (AI) in medical physics and oncology. This episode explores how AI technologies not only support but significantly enhance diagnostic and treatment processes in healthcare, particularly in the complex field of oncology. Tune in as we examine the practical and potential applications of AI in transforming patient care and treatment efficiency."What the algorithm is going to do is going to look at the history of similar patients that went through that process. We recognize every patient is unique. Every patient needs may be different. And this is where there is a lot of uncertainty with the prediction that their algorithm is going to do it." - Dr. El NaqaKey Points From This Episode:Dr. El Naqa's transition from electrical engineering to medical physicsThe integration of AI in enhancing diagnostic imaging and treatment planningAI's role in medical physics, historically and presentlyDiscussion on the evolution of AI tools in medical applicationsExamining AI's effectiveness in non-invasive cancer treatmentsHow AI supports personalized patient care in oncologyAI in the optimization of medical processes and patient managementFuture perspectives on AI's role in healthcare from Dr. El NaqaThe balance between AI capabilities and human expertise in medicine

Join us for an enlightening discussion with Marc Perkins-Carrillo, Chief Nursing Informatics Officer at Moffitt Cancer Center, as he shares his background and recent successful projects. Marc delves into his priorities for the next 12 months and anticipates changes in his role and teams, providing valuable insights into nursing informatics in oncology care.